No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
This company specializes in the development of innovative regenerative bio-orthopedic products. Its current pipeline includes BiG-001 and BiG-006, both of which are osteoinductive bone graft substitutes. Additionally, it is advancing BiG-009, an autologous cartilage repair system. Established in 2016, the firm's operations are based in Taipei, Taiwan.
www.biogend.comNo one on the platform currently holds 6733.TWO.
No tracked institution reports a position in 6733.TWO as of their last filing.
No one on the platform has traded 6733.TWO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 32.6% | 175.8% | ||||
| Profit Margin % | -38.1% | -466.1% | ||||
| Free Cash Flow Margin % | -29.5% | -463.3% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $260M | +19.3% | $-0.27 | $-0.27–$-0.27 | — | 1 |
| 2027 | $303M | +16.5% | $0.01 | $0.01–$0.01 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $-0.17 | $-0.18 | -4.9% |
| 2026-05-06 | $-0.13 | $-0.13 | +0.0% |
| 2026-02-24 | $-0.10 | $-0.18 | -80.6% |
| 2025-11-06 | $-0.09 | $-0.06 | +38.0% |
| 2025-08-07 | $-0.18 | $-0.19 | -5.6% |
| 2025-05-07 | $-0.16 | $-0.27 | -68.8% |
| 2025-02-25 | $-0.23 | $-0.32 | -39.1% |
| 2024-11-08 | $-0.18 | $-0.25 | -38.9% |
| $8.95 |
| +2.99% |
| $6.4B |
| — |
| 4167.TWOSavior Lifetec Corp. | $19.10 | +0.26% | $6.3B | — |
| 6492.TWOSenhwa Biosciences, Inc. | $33.80 | +1.50% | $3.1B | — |
Source: Financial Modeling Prep · peers by sector/industry